Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.
Type
ArticleAuthor/s
Cromer, DeborahReynaldi, Arnold
Steain, Megan
Triccas, James A
Davenport, Miles P
Khoury, David S
Abstract
The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other mRNA vaccines. Here we show that the low efficacy follows from the dose used and the presence of SARS-CoV-2 variants, and is predicted by the neutralising antibody response induced by the vaccine.The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other mRNA vaccines. Here we show that the low efficacy follows from the dose used and the presence of SARS-CoV-2 variants, and is predicted by the neutralising antibody response induced by the vaccine.
See less
See less
Date
2022Share